DOCSLIB.ORG

Allgemeine Innere Medizin / Médecine Interne Générale Abstracts

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Allgemeine Innere Medizin / Médecine Interne Générale Abstracts Primary and HospitalCare Allgemeine Innere Medizin / Médecine interne générale Supplementum 7 2. Frühjahrskongress der SGAIM ad Primary and Hospital Care 2ème congrès de printemps SSMIG 2017;17: Heft 8 / numéro 8 26. April 2017 / 26 avril 2017 Lausanne (Switzerland), 3.–5. Mai 2017 / 3–5 mai 2017 Abstracts Offizielles Organ Schweizerische Gesellschaft für Allgemeine Innere Medizin Haus- und Kinderärzte Schweiz www.primary-hospital-care.ch INHALTSVERZEICHNIS / TABLE DES MATIÈRES 1 S Freie Mitteilungen SGAIM / Communications libres SSMIG 3 S FM228–FM231 Recherche, formation, organisation et système de santé I / Forschung, Fortbildung, Organisation und Gesundheitssystem I 4 S FM232–FM236 Médecine de famille / Hausarztmedizin 6 S FM237–FM241 Médecine interne générale hospitalière / Stationäre Allgemeine Innere Medizin 8 S FM242–FM246 Epidemiologie 11 S FM247–FM251 Médecine interne générale ambulatoire / Ambulante Allgemeine Innere Medizin 13 S FM252–FM256 Future research in epidemiology 15 S FM257–FM260 Recherche, formation, organisation et système de santé II / Forschung, Fortbildung, Organisation und Gesundheitssystem II 16 S FM261–FM264 Médecine specialisée I / Fachmedizin I 18 S FM265–FM268 Médecine specialisée II / Fachmedizin II 19 S FM269–FM274 Meilleures communications libres / Beste Freie Mitteilungen Gastgesellschaft SFGG / Société conviée SPSG 22 S FM275–FM282 Communications libres / Freie Mitteilungen Gastgesellschaft SGH / Société conviée SSH 24 S 183–185 Presidential Symposium 25 S FM283–FM300 Quick Oral Presentations 33 S FM301–FM305 Free contributions: Experimental Hematology 35 S FM306–FM310 Free contributions: Hemostasis, Vascular Biology, Transfusion Medicine 37 S FM311–FM315 Free contributions: Clinical Hematology Gastgesellschaft SGKPT / Société conviée SSPTC 39 S P493–P509 Poster Presentation Session Poster SGAIM / Posters SSMIG 45 S P316–P325 10 meilleurs posters / 10 beste Poster 49 S P326–P335 Postertour 1: Médecine interne générale II / Allgemeine Innere Medizin II 53 S P336–P345 Postertour 1: Médecine interne générale III / Allgemeine Innere Medizin III 57 S P346–P355 Postertour 1: Médecine interne générale IV / Allgemeine Innere Medizin IV 60 S P356–P365 Postertour 1: Médecine interne générale I / Allgemeine Innere Medizin I 64 S P366–P375 Postertour 2: Médecine interne générale / Allgemeine Innere Medizin / Médecine specialisée / Fachmedizin 68 S P376–P385 Postertour 2: Médecine specialisée I / Fachmedizin I 71 S P386–P395 Postertour 2: Médecine specialisée II / Fachmedizin II 75 S P396–P403 Postertour 2: MIG ambulatoire / Ambulante AIM / Médecine de famille I / Hausarztmedizin I 78 S P404–P412 Postertour 2: Médecine interne générale V / Allgemeine Innere Medizin V 81 S P413–P422 Postertour 3: Médecine specialisée IV / Fachmedizin IV 85 S P423–P432 Postertour 3: Médecine specialisée V / Fachmedizin V PRIMARY AND HOSPITAL CARE – ALLGEMEINE INNERE MEDIZIN 2017;17(SUPPLEMENTUM) INHALTSVERZEICHNIS / TABLE DES MATIÈRES 2 S 88 S P433–P442 Postertour 3: MIG ambulatoire II / Ambulante AIM II / Médecine de famille II / Hausarztmedizin II 91 S P443–P451 Postertour 3: MIG ambulatoire III / Ambulante AIM III / Médecine de famille III / Hausarztmedizin III 94 S P452–P461 Postertour 3: Médecine specialisée III / Fachmedizin III Gastgesellschaft SFGG / Société conviée SPSG 98 S P462–P463 Poster SFGG / Posters SPSG Gastgesellschaft SGH / Société conviée SSH 98 S P464–P492 Poster presentations Gastgesellschaft SGKPT / Société conviée SSPTC 109 S P510–P523 Poster Index of first authors 116 S Impressum Primary and Hospital Care Marketing EMH / Inserate: © EMH Schweizerischer Ärzteverlag AG Hinweis: Alle in dieser Zeitschrift Offizielles Organ von mfe Haus- und Dr. phil. II Karin Würz, Leiterin (EMH), 2017. «Primary and Hospital publizierten Angaben wurden mit der Kinderärzte Schweiz, der Schweizeri- Marketing und Kommunikation, Care» ist eine Open- Access-Publika- grössten Sorgfalt überprüft. Die mit schen Gesellschaft für Allgemeine Tel. +41 (0)61 467 85 49, Fax +41 (0)61 tion von EMH. Entsprechend gewährt Verfassernamen gezeichneten Veröf- Innere Medizin SGAIM, der Schweize- 467 85 56, [email protected] EMH allen Nutzern auf der Basis der fentlichungen geben in erster Linie rischen Gesellschaft für Pädiatrie SGP, Creative-Commons-Lizenz «Namens- die Auffassung der Autoren und nicht des Kollegiums für Hausarztmedizin Abonnemente: EMH Schweizerischer nennung – Nicht kommerziell – Keine zwangsläufig die Meinung der Redak- KHM, der Schweize rischen Akademie Ärzteverlag AG, Abonnemente, Bearbeitungen 4.0 International» das tion von PrimaryCare wieder. Die an- für Psychosoma tische und Psycho- Farnsburgerstrasse 8, 4132 Muttenz, zeitlich unbeschränkte Recht, das Werk gegebenen Dosierungen, Indikationen soziale Medizin SAPPM sowie der Tel. +41 (0)61 467 85 75, Fax +41 zu vervielfältigen, zu verbreiten und und Applikationsformen, vor allem von Jungen Hausärztinnen und -ärzte (0)61 467 85 76, [email protected] öffentlich zugänglich zu machen unter Neuzulassungen, sollten in jedem Fall Schweiz JHaS. Abonnementspreise: Für Mitglieder den Bedingungen, dass (1) der Name mit den Fachinformationen der ver- Redaktionsadresse: Ruth Schindler, der Herausgebergesellschaften gelten des Autors genannt wird, (2) das Werk wendeten Medikamente verglichen Redaktionsassistentin, EMH Schweize- spezielle Konditionen, die im Detail nicht für kommerzielle Zwecke ver- werden. rischer Ärzteverlag AG, Farnsburger- unter http://www.primary-care.ch/ wendet wird und (3) das Werk in keiner strasse 8, 4132 Muttenz, Tel. +41 (0)61 fuer-leser/abonnement/ zu finden sind. Weise bearbeitet oder in anderer Herstellung: Schwabe AG, Muttenz, 467 85 58, Fax +41 (0)61 467 85 56, Weise verändert wird. Die kommer- www.schwabe.ch [email protected], Abonnemente für Nichtmitglieder: zielle Nutzung ist nur mit ausdrück- www.primary-hospital-care.ch CHF 125.–, Studentenabonnement licher vorgängiger Erlaubnis von EMH Manuskripteinreichung online: CHF 63.–, jeweils zuzüglich Porto. und auf der Basis einer schriftlichen http://www.edmgr.com/primarycare Vereinbarung zulässig. ISSN: Printversion: 2297-7155 / Verlag: EMH Schweizerischer Ärzte- elektronische Ausgabe: 2297-7163 Cover photo: verlag AG, Farnsburgerstrasse 8, Erscheinungsweise: 23 Ausgaben ©Daniel Brigginshaw | 4132 Muttenz, Tel. +41 (0)61 467 85 55, pro Jahr. Dreamstime.com Fax +41 (0)61 467 85 56, www.emh.ch FREIE MITTEILUNGEN SGAIM / COMMUNICATIONS LIBRES SSMIG 3 S RECHERCHE, FORMATION, ORGANISATION ET SYSTÈME DE SANTÉ I / FORSCHUNG, FORTBILDUNG, ORGANISATION UND GESUNDHEITSSYSTEM I FM228 Results: 86 clinical supervisors finished the training (participation rate Rates, delays and completeness of general 95%). Preliminary results show that participants’ satisfaction with the practitioners’ responses to a postal versus training was similar in both groups. There was no change in motivation web-based survey: a randomized trial to teach or give feedback after training among both groups (sum of 1 1 2 means – traditional: pre 37.97 (SD 3.64) vs post 37.19 (SD 4.73) p = Paul Sebo , Hubert Maisonneuve , Bernard Cerutti , 0.28; experiential: pre 37.8 (SD 4.19) vs post 37.8 (SD 3.18) p = 1.00). Jean Pascal Fournier3, Nicolas Senn4, Dagmar M Haller Esther1 1 Both groups expressed higher self-efficacy regarding their ability to Unité des Internistes Généralistes et Pédiatres / Université de teach or give feedback in the post-intervention phase (sum of means Genève; 2Unité de Développement et de Recherche en Éducation 3 – traditional: pre 94.86 (SD 17.44) vs 106.71 (14.27) p <0.001; Médicale, Faculté de Médecine, Genève, Switzerland; Département experiential: 90.85 (SD 19.92) vs 103.94 (SD 10.33), p <0.001). de Médecine Générale, Faculté de Médecine, Université de Nantes, 4 Objective analysis of participants’ teaching skills is still ongoing and Nantes, France; Institut Universitaire de Médecine de Famille, the final results will be presented at the conference. Lausanne, Switzerland Discussion: Training junior clinical supervisors on how to supervise Background: Web-based surveys became a new and popular method and give feedback is effective. The additional impact of individual for collecting data, but only few studies directly compared postal and coaching versus simple workshops is still uncertain. web-based surveys among physicians, and none to our knowledge among general practitioners (GPs). Objective: To compare two modes of survey delivery (postal and FM230 web-based) in terms of participation rates, response times and Do early handoffs in internal medicine wards affect completeness of questionnaires in a study assessing GPs’ preventive the quality and cost of care? practices. Christophe Fehlmann1, Martine Louis Simonet1, Christophe Methods: This randomized study was conducted in Western 2 1 1,3 Switzerland (Geneva and Vaud) and in France (Alsace and Pays de la Gaudet-Blavignac , Jérôme Stirnemann , Katherine Blondon 1Service de Médecine Interne Générale, DMIRG, HUG; 2Service des Loire) in 2015. A random selection of community-based GPs (1000 3 GPs in Switzerland and 2400 GPs in France) were randomly allocated Sciences de l’Information Médicale, DISIM, HUG; Direction Médicale, to receive a questionnaire about preventive care activities either by HUG, Genève, Switzerland post (n = 700 in Switzerland, n = 400 in France) or by e-mail (n = 300 Introduction: Continuity of care is a key feature for high quality of in Switzerland, n = 2000 in France). Reminder messages were sent care. To maintain the continuity of care of patients
Load more

Recommended publications
  • Deliverable 5.A Interim Report on the Study Results APPENDIX 2
    Deliverable 5.a Interim report on the study results APPENDIX 2: Algorithms used to identify study variables for service contract EMA/2011/38/CN ‐ PIOGLITAZONE November 28th 2012 D5.a Interim report on the study results (Appendix 2) for Service Contract EMA/2011/38/CN PIOGLITAZONE Author(s): Vera Ehrenstein (AUH‐AS) APPENDIX 2. ALGORITHMS USED TO IDENTIFY STUDY VARIABLES Algorithms for AU Database DISEASE/CONDITION ICD-8 CODE (1977-1993) ICD-10 CODE (1994-) Diabetes type 2 250.00; 250.06; 250.07; 250.09 E11.0; E11.1; E11.9 Cancer of bladder 188 C67 Haematuria N/A R31 Haematuria, unspecified B18, K70.0–K70.3, K70.9, K71, K73, Mild hepatic impairment 571, 573.01, 573.04 K74, K76.0 Moderate to severe hepatic 070.00, 070.02, 070.04, 070.06, B15.0, B16.0, B16.2, B19.0, K70.4, impairment 070.08, 573.00, 456.00–456.09 K72, K76.6, I85 Acute myocardial infarction 410 I21-I23 Acute coronary syndrome 410, 413 I20-I24 Ischemic heart disease 410-414 I20-I25 427.09, 427.10, 427.11, 427.19, Congestive heart failure I50, I11.0, I13.0,I13.2 428.99, 782.49; Acute renal failure N/A N17 Diabetic coma N/A E10.0, E11.0, E12.0,E13.0, E14.0 Diabetic acidosis N/A E10.1, E11.1, E12.1,E13.1, E14.1 F10.1-F10.9, G31.2, G62.1, G72.1, Alcoholism 291, 303, 577.10, 571.09, 571.10 I42.6, K29.2, K86.0, Z72.1 Obesity 277.99 E65-E66 D5.a Interim report on the study results (Appendix 2) for Service Contract EMA/2011/38/CN PIOGLITAZONE Author(s): Vera Ehrenstein (AUH‐AS) Algorithms for defining acute events in Denmark, ICD-10 code Event ICD-10 code I21.x, I23.x http://apps.who.int/classifications/icd10/browse/2010/en#/I21
    [Show full text]
  • Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients with Renal Dysfunction
    http://www.diva-portal.org This is the published version of a paper published in Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease. Citation for the original published paper (version of record): Szummer, K., Gasparini, A., Eliasson, S., Ärnlöv, J., Qureshi, A R. et al. (2017) time in therapeutic range and outcomes after warfarin initiation in newly diagnosed atrial fibrillation patients with renal dysfunction. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 6(3): e004925 https://doi.org/10.1161/JAHA.116.004925 Access to the published version may require subscription. N.B. When citing this work, cite the original published paper. Permanent link to this version: http://urn.kb.se/resolve?urn=urn:nbn:se:du-24516 ORIGINAL RESEARCH Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction Karolina Szummer, MD, PhD; Alessandro Gasparini, MSc; Staffan Eliasson, MD; Johan Arnl€ ov,€ MD, PhD; Abdul Rashid Qureshi, MD, PhD; Peter Barany, MD, PhD; Marie Evans, MD, PhD; Leif Friberg, MD, PhD; Juan Jesus Carrero, PharmMed, PhD Background-—It is unknown whether renal dysfunction conveys poor anticoagulation control in warfarin-treated patients with atrial fibrillation and whether poor anticoagulation control associates with the risk of adverse outcomes in these patients. Methods and Results-—This was an observational study from the Stockholm CREatinine Measurements (SCREAM) cohort including all newly diagnosed atrial fibrillation patients initiating treatment with warfarin (n=7738) in Stockholm, Sweden, between 2006 and 2011. Estimated glomerular filtration rate (eGFR; mL/min per 1.73 m2) was calculated from serum creatinine.
    [Show full text]
  • Evaluating Onco-Geriatric Scores and Medication Risks to Improve Cancer Care for Older Patients
    Evaluating onco-geriatric scores and medication risks to improve cancer care for older patients Dissertation zur Erlangung des Doktorgrades (Dr. rer. nat.) der Mathematisch-Naturwissenschaftlichen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn vorgelegt von IMKE ORTLAND aus Quakenbrück Bonn 2019 Angefertigt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn. Diese Dissertation ist auf dem Hochschulschriftenserver der ULB Bonn elektronisch publiziert. https://nbn-resolving.org/urn:nbn:de:hbz:5-58042 Erstgutachter: Prof. Dr. Ulrich Jaehde Zweitgutachter: Prof. Dr. Andreas Jacobs Tag der Promotion: 28. Februar 2020 Erscheinungsjahr: 2020 Danksagung Auf dem Weg zur Promotion haben mich viele Menschen begleitet und in ganz unterschiedlicher Weise unterstützt. All diesen Menschen möchte ich an dieser Stelle ganz herzlich danken. Mein aufrichtiger Dank gilt meinem Doktorvater Prof. Dr. Ulrich Jaehde für das in mich gesetzte Vertrauen, sowie für die Überlassung dieses spannenden Dissertationsthemas. Die uneingeschränkte Unterstützung, wertvollen Diskussionen und die mitreißende Begeisterung für die Wissenschaft haben mich während aller Phasen der Dissertation stets motiviert, unterstützt und sehr viel Wertvolles gelehrt. Prof. Dr. Andreas Jacobs danke ich herzlich für die Initiierung dieses interessanten Projekts, für die stetige Begeisterung und Unterstützung, sowie für das mir entgegengebrachte Vertrauen. Die ausgezeichnete Zusammenarbeit mit dem Johanniter Krankenhaus Bonn hat ganz maßgeblich zum Gelingen dieser Arbeit beigetragen. Auch danke ich Prof. Dr. Andreas Jacobs herzlich für die Bereitschaft, das Koreferat dieser Arbeit zu übernehmen. Ebenfalls danke ich herzlich Prof. Dr. Yon-Dschun Ko für seine fortwährende Motivation und seinen Einsatz, sowie für das mir geschenkte Vertrauen, dieses Projekt am Johanniter Krankenhaus zu realisieren. Ebenfalls danke ich Prof.
    [Show full text]
  • Perioperative Management of Patients Treated with Antithrombotics in Oral Surgery
    SFCO/Perioperative management of patients treated with antithrombotic agents in oral surgery/Rationale/July 2015 SOCIÉTÉ FRANÇAISE DE CHIRURGIE ORALE [FRENCH SOCIETY OF ORAL SURGERY] IN COLLABORATION WITH THE SOCIÉTÉ FRANÇAISE DE CARDIOLOGIE [FRENCH SOCIETY OF CARDIOLOGY] AND THE PERIOPERATIVE HEMOSTASIS INTEREST GROUP Space Perioperative management of patients treated with antithrombotics in oral surgery. RATIONALE July 2015 P a g e 1 | 107 SFCO/Perioperative management of patients treated with antithrombotic agents in oral surgery/Rationale/July 2015 Abbreviations ACS Acute coronary syndrome(s) ADP Adenosine diphosphate Afib Atrial Fibrillation AHT Arterial hypertension Anaes Agence nationale d’accréditation et d’évaluation en santé [National Agency for Accreditation and Health Care Evaluation] APA Antiplatelet agent(s) aPTT Activated partial thromboplastin time ASA Aspirin BDMP Blood derived medicinal products BMI Body mass index BT Bleeding Time cAMP Cyclic adenosine monophosphate COX-1 Cyclooxygenase 1 CVA Cerebral vascular accident DIC Disseminated intravascular coagulation DOA Direct oral anticoagulant(s) DVT Deep vein thrombosis GEHT Study Group on Hemostasis and Thrombosis (groupe d’étude sur l’hémostase et la thrombose) GIHP Hemostasis and Thrombosis Interest Group (groupe d’intérêt sur l’hémostase et la thrombose) HAS Haute autorité de santé [French Authority for Health] HIT Heparin-induced thrombocytopenia IANB Inferior alveolar nerve block INR International normalized ratio IV Intravenous LMWH Low-molecular-weight heparin(s)
    [Show full text]
  • Malaysian STATISTICS on MEDICINE 2005
    Malaysian STATISTICS ON MEDICINE 2005 Edited by: Sameerah S.A.R Sarojini S. With contributions from Goh A, Faridah A, Rosminah MD, Radzi H, Azuana R, Letchuman R, Muruga V, Zanariah H, Oiyammal C, Sim KH, Fong AYY, Tamil Selvan M, Basariah N, Hooi LS, Zaki Morad, Fadilah O, Lim V.K.E., Tan KK, Biswal BM, Lim YS, Lim GCC, Mohammad Anwar H.A, Ahmad Sabri O, Mary SC, Marzida M, Benjamin Chan TM, Suarn Singh, Zoriah A, Noor Ratna N , Abdul Razak M, Norzila Z, Shamsinah H A publication of the Pharmaceutical Services Division and the Clinical Research Centre Ministry of Health Malaysia Malaysian Statistics On Medicine 22005005 Edited by: Sameerah S.A.R Sarojini S. With contributions from Goh A, Faridah A, Rosminah MD, Radzi H, Azuana R, Letchuman R, Muruga V, Zanariah H, Oiyammal C, Sim KH, Fong AYY, Tamil Selvan M, Basariah N, Hooi LS, Zaki Morad, Fadilah O, Lim V.K.E., Tan KK, Biswal BM, Lim YS, Lim GCC, Mohammad Anwar H.A, Ahmad Sabri O, Mary SC, Marzida M, Benjamin Chan TM, Suarn Singh, Zoriah A, Noor Ratna N , Abdul Razak M, Norzila Z, Shamsinah H A publication of the Pharmaceutical Services Division and the Clinical Research Centre Ministry of Health Malaysia Malaysian Statistics On Medicine 2005 April 2007 © Ministry of Health Malaysia Published by: The National Medicines Use Survey Pharmaceutical Services Division Lot 36, Jalan Universiti 46350 Petaling Jaya Selangor, Malaysia Tel. : (603) 4043 9300 Fax : (603) 4043 9400 e-mail : [email protected] Web site : http://www.crc.gov.my/nmus This report is copyrighted.
    [Show full text]
  • Presentazione Standard Di Powerpoint
    EVALUATION OF ADHERENCE TO NEW ORAL ANTICOAGULANTS THERAPY BASED ON THERAPEUTIC SWITCHES: A DESCRIPTIVE STUDY. L. Gasperoni1, F. Ambrosini Spinella1, A.M. Resta1. 1 ASUR Marche, Territorial Pharmaceutical Service AV1, Fano, Italy Abstract number: 5PSQ-011 ATC code: B01 - Antithrombotic agents Background Regarding therapeutic adherence to new oral ITALY: the prescription of NOAC is possible from anticoagulants (NOAC), several studies [1] have shown Dabigatram July 2013 lower adherence in Dabigatran treated patients compared to Rivaroxaban and Apixaban. The NOAC Rivaroxaban October 2013 introduction has fueled the phenomenon of switch Apixaban March 2014 from vitamin K antagonists (VKA) to NOAC, and vice Edoxaban October 2016 versa, and also from NOAC to other NOAC. Purpose The aim of this descriptive study is to evaluate adherence to therapy among NOAC treated patients by basing the analysis on the therapeutic switches, ie the passages to another NOAC or VKA. Material and methods Through the informatic flow of pharmaceutical prescriptions, we extracted the NOAC prescriptions from July 2013 to June 2016 in the Area Vasta 1 of the Region. Patients who have taken Dabigatran, Rivaroxaban and Apixaban have emerged from these prescriptions (Edoxaban is excluded because it is available since October 2016). Adherent patient was that who did not switch to other anticoagulant therapy (NOAC or VKA) during the analysis period and in the following 6 months (until December 2016). Patients who had taken VKA before starting treatment with NOAC (the flow of prescriptions was investigated since January 2013) and patients who died during the analysis period or in the following 6 months were excluded from the study.
    [Show full text]
  • Neuraxial Blockade and Anticoagulants
    Soli Deo Gloria NEURAXIAL BLOCKADE AND ANTICOAGULANTS Developing Countries Regional Anesthesia Lecture Series Lecture 4 Daniel D. Moos CRNA, Ed.D. U.S.A. [email protected] Disclaimer Every effort was made to ensure that material and information contained in this presentation are correct and up-to-date. The author can not accept liability/responsibility from errors that may occur from the use of this information. It is up to each clinician to ensure that they provide safe anesthetic care to their patients. INTRODUCTION Benefits of Neuraxial Blockade Decreased nausea and vomiting Decreased blood loss Decreased incidence of graft occlusion Improved mobility after major knee surgery Superior postoperative pain control Less alteration to the cardiopulmonary status of the patient The need for formalized guidance for anticoagulated patient: Advances in pharmacology Desire to prevent thromboembolism Formulation of thromboembolism prophylaxis Use of regional anesthesia ASRA Guidelines 1998 the first Consensus Conference on Neuraxial Anesthesia and Analgesia was held. 2002 the second Consensus Conference was held. The result: formalized guidelines to assist the anesthesia provider in decision making. THROMBOPROPHYLAXIS Medications for total joint thromboprophylaxis Unfractionated heparin Low molecular weight heparin (ardeparin sodium or Normoflo®, dalteparin sodium or Fragmin®, danaparoid sodium or Orgaran®, enoxaprin sodium or Lovenox® and tinzaprin or Innohep®). Warfarin sodium Medications for general surgery thromboprophylaxis
    [Show full text]
  • Annex I Summary of Product Characteristics
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Revasc 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial of Revasc contains 15 mg desirudin (INN) corresponding to approximately 270 000 antithrombin units (ATU) or 18 000 ATU per mg of desirudin with reference to the WHO Second International Standard for α-thrombin. Desirudin is a recombinant DNA product derived from yeast cells. Desirudin is a single chain polypeptide consisting of 65 amino acid residues and 3 disulphide bridges. Vials of desirudin are supplied with solvent ampoules containing pyrogen-free Mannitol Ph. Eur. in Water for injections Ph. Eur. 3. PHARMACEUTICAL FORM Powder for injection to be reconstituted prior to subcutaneous injection with 0.5 ml mannitol solvent for solution (3%) which is supplied with the product. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Prevention of deep venous thrombosis in patients undergoing elective hip and knee replacement surgery. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Adult and elderly patients The recommended dose is 15 mg twice daily. The first injection should be initiated 5 to 15 minutes before surgery but after induction of regional block anaesthesia, if used. Treatment with desirudin is then continued twice daily post-operatively for 9 to a maximum of 12 days or until the patient is fully ambulant, whichever occurs first. Currently, there is no clinical experience to support the use of desirudin beyond 12 days. Administration is by subcutaneous injection, preferably at an abdominal site. Injections should be rotated between at least four different sites. Children There is no clinical experience with desirudin in children.
    [Show full text]
  • Glycoprotein Iib/Iiia Inhibitors During Percutaneous Coronary Interventions
    REVIEW Glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions Intravenous glycoprotein IIb/IIIa inhibitors are widely used during percutaneous coronary interventions (PCIs). There are three commercially available pharmacological agents: abciximab, eptifibatide and tirofiban. This article presents the evidence indicating their use in connection with PCI, and focuses on the differences between the three regimens, as well as on their use in special clinical conditions. The documentation for their use in high-risk PCI (in other words, for acute coronary syndromes and complex coronary anatomy), and in primary PCI for ST-elevation myocardial infarction will be scrutinized, as well as the use of intracoronary administration. Furthermore, the role of glycoprotein IIb/IIIa inhibitors as opposed to, or in combination with, thienopyridines and thrombin inhibitors will be analyzed, as will their use in diabetics, in patients with renal insufficiency and when performing PCI in vein grafts. Finally, the possible effects of glycoprotein IIb/IIIa inhibitors on restenosis and inflammation, as well as dosing and bleeding issues will be discussed. †1 KEYWORDS: abciximab n eptifibatide n glycoprotein IIb/IIIa inhibitor n myocardial Michael Koutouzis infarction n percutaneous coronary intervention n tirofiban & Lars Grip1 1Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden Percutaneous coronary intervention, to be developed and brought forward for clini- †Author for correspondence: coronary thrombosis & development cal use [6,7]. Abciximab has a high molecular Tel.: +46 313 427 565 Fax: +46 3182 0062 of glycoprotein IIb/IIIa inhibitors weight of more than 47,000 Da, a high affinity [email protected] Percutaneous coronary intervention (PCI) was to the GP IIb/IIIa receptor and a relatively short introduced as balloon dilatation by Grüntzig in plasma half-life (20–30 min).
    [Show full text]
  • Clexane® 2.000 IE – 10.000 IE / Clexane® Multidose 50.000 IE
    FACHINFORMATION Clexane ® Clexane ® multidose 1. BEZEICHNUNG DER ARZNEIMITTEL Clexane multidose 100.000 I. E. (1000 mg)/ 4.2 Dosierung und Art der Anwendung 10 ml Injektionslösung und Clexane multi- Clexane 2.000 I. E. (20 mg)/0,2 ml Dosierung dose 100.000 I. E. (1000 mg)/10 ml Praxis Injektionslösung in einer Fertigspritze Prophylaxe venöser thromboembolischer Injektionslösung Clexane 2.000 I. E. (20 mg)/0,2 ml Klinik Erkrankungen bei chirurgischen Patienten Eine Durchstechflasche enthält 100.000 I. E. Injektionslösung in einer Fertigspritze mit mäßigem und hohem Risiko Clexane 2.000 I. E. (20 mg)/0,2 ml Praxis Anti-Xa-Aktivität Enoxaparin-Natrium (ent- Durch ein validiertes Risikostratifizierungs- Injektionslösung in einer Fertigspritze sprechend 1000 mg) + 150 mg Benzylal- modell kann ein individuelles Thromboem- Clexane 4.000 I. E. (40 mg)/0,4 ml kohol in 10,0 ml Wasser für Injektionszwecke. bolierisiko abgeschätzt werden. Injektionslösung in einer Fertigspritze • Bei Patienten mit mäßigem Risiko für Clexane multidose Clexane 4.000 I. E. (40 mg)/0,4 ml Klinik Thromboembolien beträgt die empfohlene Sonstiger Bestandteil mit bekannter Wir- Injektionslösung in einer Fertigspritze Dosis einmal täg lich 2.000 I. E. (20 mg) Clexane 4.000 I. E. (40 mg)/0,4 ml Praxis kung: Benzylalkohol. Enoxaparin-Natrium mittels subkutaner Injektionslösung in einer Fertigspritze Dieses Arzneimittel enthält 15 mg Benzyl- (s. c.) Injektion. Eine präoperative Gabe Clexane 6.000 I. E. (60 mg)/0,6 ml Injektions- alkohol pro 1 ml (siehe Abschnitte 4.3, 4.4 der ersten Injektion (zwei Stunden vor lösung in einer Fertigspritze und 4.8). Benzylalkohol kann allergische der Operation) von 2.000 I.
    [Show full text]
  • Advances in Interventional Cardiology New Directions In
    Advances in Interventional Cardiology New Directions in Antiplatelet Therapy Jose´ Luis Ferreiro, MD; Dominick J. Angiolillo, MD, PhD therosclerosis is a chronic inflammatory process that is A2 (TXA2) from arachidonic acid through selective acetylation Aknown to be the underlying cause of coronary artery of a serine residue at position 529 (Ser529). TXA2 causes disease (CAD).1 In addition to being the first step of primary changes in platelet shape and enhances recruitment and aggre- hemostasis, platelets play a pivotal role in the thrombotic gation of platelets through its binding to thromboxane and process that follows rupture, fissure, or erosion of an athero- prostaglandin endoperoxide (TP) receptors. Therefore, aspirin sclerotic plaque.2 Because atherothrombotic events are essen- decreases platelet activation and aggregation processes mediated tially platelet-driven processes, this underscores the impor- by TP receptor pathways.7 tance of antiplatelet agents, which represent the cornerstone Although the optimal dose of aspirin has been the subject of treatment, particularly in the settings of patients with acute of debate, the efficacy of low-dose aspirin is supported by the coronary syndromes (ACS) and undergoing percutaneous results of numerous studies.8–10 In these investigations, a coronary intervention (PCI). dose-dependent risk for bleeding, particularly upper gastro- Currently, there are 3 different classes of antiplatelet drugs that are approved for clinical use and recommended per intestinal bleeding, with no increase in
    [Show full text]
  • Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current
    Bench to Clinic Symposia EDITORIAL REVIEW Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions DOMINICK J. ANGIOLILLO, MD, PHD of low-dose aspirin (75–162 mg/day) as a primary prevention strategy in patients with type 1 or type 2 diabetes at increased Ͼ ardiovascular disease is the leading patients undergoing percutaneous coro- cardiovascular risk, including those 40 cause of morbidity and mortality in nary interventions (PCI) (4). However, years of age or who have additional risk C patients with diabetes (1). The con- these agents are available only for paren- factors (family history of cardiovascular comitant presence of multiple classical teral use and have a short duration of ac- disease, hypertension, smoking, dyslipi- cardiovascular risk factors in diabetic tion, which impedes their use for long- demia, or albuminuria) (8). However, subjects contributes to enhanced athero- term protection. The need for alternative aspirin therapy should not be recom- thrombotic risk (2). However, other risk antiplatelet treatment strategies led to the mended for patients aged Ͻ21 years be- factors may be important such as abnor- evaluation of effects obtained from a com- cause this may increase the risk of Reye’s mal platelet function (3). Platelets, in fact, bination of oral antiplatelet agents inhib- syndrome. The role of aspirin in diabetic play a key role in atherogenesis, and its iting other platelet-activating pathways. patients aged Ͻ30 years remains unclear thrombotic complications and measures, Ticlopidine is a first-generation thienopy- because it has not been investigated. which lead to blockade of one or multiple ridine, which irreversibly blocks the Several clinical trials have evaluated the efficacy of aspirin in diabetic patients pathways modulating platelet activation platelet ADP P2Y12 receptor (6).
    [Show full text]